Showing 5211-5220 of 10177 results for "".
- AAD Releases New Melanoma Guidelineshttps://practicaldermatology.com/news/aad-releases-new-melanoma-guidelines/2457522/As National Healthy Skin Month begins, the American Academy of Dermatology’s (AAD) new melanoma guidelines shed light on risk of melanoma prognosis during pregnancy, the role of formal genetic testing in at-risk families and other aspects of care for primary cutaneous melanoma.
- AlmirallShare Issues Call for Proposalshttps://practicaldermatology.com/news/almirallshare-issues-call-for-proposals/2457571/Almirall is seeking to find novel targets and concepts in the treatment of dermatological diseases. The company’s AlmirallShare open innovation platform is calling for proposals from October 10, 2018 to February 28, 2019 from universities, research centers, start-ups, biotechs and phar
- FDA Approves Paratek's Nuzyrahttps://practicaldermatology.com/news/fda-approves-parateks-nuzyra/2457579/The FDA has approved Paratek Pharmaceuticals, Inc's Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Nuzyra, a modernized tetracycline, is a once-daily IV and or
- Dermira's Qbrexa Cloth Now Available for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-qbrexa-cloth-now-available-for-primary-axillary-hyperhidrosis/2457582/Dermira, Inc.'s Qbrexa (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis. The new therapy is available in retail and community pharmacies nationwide. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was FDA approved to treat adul
- Recros Medica Unveils the Nuvellus Brand for Its Novel Rotational Fractional Resection Technologyhttps://practicaldermatology.com/news/recros-medica-unveils-the-nuvellus-brand-for-its-novel-rotational-fractional-resection-technology/2457588/Recros Medica, Inc. is unveiling the Nuvellus brand at this week’s American Society of Plastic Surgery meeting. The company will display at booth #1264, where it will introduce Nuvellus as an innovative, minimally-invasive surgical procedure in develop
- Bellus Medical Now Part of Crown Laboratorieshttps://practicaldermatology.com/news/bellus-medical-now-part-of-crown-laboratories/2457590/Crown Laboratories, Inc. and Hildred Capital Partners, LLC have acquired Bellus Medical. Bellus’s non-invasive offerings include the SkinPen, a medical grade microneedling device used exclusively by healthcare professionals to improve the appearance of facial acne scars. It is the f
- Celebrity Manicurist Joins with Galderma for "Face Your Hands" Campaignhttps://practicaldermatology.com/news/celebrity-manicurist-deborah-lippmann-joins-with-galderma-for-face-your-hands-campaign/2457596/Galderma Laboratories, L.P.,’s Restylane® Lyft is partnering with celebrity manicurist Deborah Lippmann for the "Face Your Hands" campaign, which aims to educate women on the steps they can take to achieve more youthful hands. A
- Almirall Finalizes Acquisition of Allergan US Medical Dermatology Portfoliohttps://practicaldermatology.com/news/almirall-finalizes-acquisition-of-allergan-us-medical-dermatology-portfolio/2457600/Almirall, S.A. finalized its acquisition of products from Allergan's Medical Dermatology unit in the US: Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), and Cordran Tape (flurandrenolide). In addition, sarecycline, a New Chemical Entity (NCE) currently under FDA review for appr
- Wake Forest Researchers: #2 in Probiotic Advancementhttps://practicaldermatology.com/news/wake-forest-researchers-2-in-probiotic-advancements/2457638/Scientists at Wake Forest School of Medicine say they have developed a probiotic “cocktail” derived from gut bacteria strains found in infant feces that may help increase the body’s ability to produce short-chain fatty acids (SCFAs). “Short-chain fa
- MC2 Therapeutics Reports Positive Topline Data for Investigational Topical for Psoriasishttps://practicaldermatology.com/news/mc2-therapeutics-reports-positive-topline-data-for-investigational-topical-for-psoriasis/2457641/MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics A/S achieved its primary and secondary endpoints, according to recently reported top-line data from the US Phase 3 study. Results of the